Trump says Zelenskiy should not target Moscow
His comments came after The Financial Times, citing people briefed on discussions, reported on Tuesday that Trump had privately encouraged Ukraine to step up deep strikes on Russia.
The newspaper added that Trump asked Zelenskiy whether he could strike Moscow if the U.S. provided long-range weapons.
"No, he shouldn't target Moscow," Trump told reporters on the South Lawn of the White House when asked if Zelenskiy should attack the Russian capital.
Trump on Monday announced a toughened stance against Russia for its three-year-old war in Ukraine, promising a fresh wave of missiles and other weaponry for Ukraine. He gave Moscow 50 days to reach a ceasefire or face sanctions.
Asked if he was now on the side of Ukraine, Trump said, "I am on nobody's side," and then declared he was on "humanity's side" because "I want to stop the killing."
Trump defended the deadline he set for Russia to agree to a deal and head off tariffs and sanctions on countries that buy oil from Russia.
"I don't think 50 days is very long and it could be sooner than that," he said.
He did not say whether any talks were planned to try to work out a deal with Russia.
"At the end of the 50 days if we don't have a deal, it's going to be too bad," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
Russia attacks Ukraine with hundreds of drones, energy infrastructure hit
KYIV, July 16 (Reuters) - Russia attacked cities across Ukraine overnight with hundreds of drones and a missile strike, hitting energy infrastructure and wounding at least 15 people, authorities said on Wednesday. Ukraine's air force said Russia launched 400 drones and one ballistic missile, primarily targeting Kharkiv, Kryvyi Rih and Vinnytsia - three cities in different parts of Ukraine. The large-scale long-range attacks targeted energy infrastructure, President Volodymyr Zelenskiy said on X. Power was cut for 80,000 families in Kryvyi Rih and other locations in the Dnipropetrovsk region, Ukraine's largest private energy company DTEK said on the Telegram app. The air force said it had shot down most of the drones, but that 12 targets were hit by 57 drones and the missile. Russia has stepped up attacks on cities across Ukraine this summer, regularly sending several hundred drones accompanied by ballistic missiles. The attacks were cited by U.S. President Donald Trump this week as a reason for his decision to approve more weapons for Ukraine, including air defences. "Russia does not change its strategy, and to effectively counter this terror we need a systemic strengthening of defences: more air defences, more interceptor (drones), more determination to make Russia feel our response," Zelenskiy wrote. In Vinnytsia and the surrounding region, eight people were wounded, according to Ukraine's interior ministry. Polish Foreign Minister Radoslaw Sikorski said on X that drones had hit a factory of the Polish wood flooring producer Barlinek Group in Vinnytsia, which is in the western part of central Ukraine. "The plant manager told me just now that it was deliberate, from three directions... Putin's criminal war is getting closer to our borders," he added. The head of the military administration in Kryvyi Rih, Oleksandr Vilkul, said Russian forces conducted an extended attack with a missile and 28 drones. He said water supplies had also been disrupted in some areas. A 17-year-old boy had been severely injured in the attack and was fighting for his life in hospital, Vilkul added. In Kharkiv, a frequent target of Russian attacks, regional Governor Oleh Syniehubov said at least 17 explosions were recorded in a 20-minute drone attack in which three people were injured. Kyiv Mayor Vitali Klitschko said air defence units had gone into action for a time in the capital, but there were no reports of casualties or damage there. Russia has killed thousands of civilians in attacks on Ukrainian cities since launching its full-scale invasion more than three years ago. Moscow says civilian infrastructure such as energy systems are legitimate targets because they help Ukraine's war effort. Ukraine also launches long-range strikes on targets in Russia, although on a more limited scale.
NBC News
an hour ago
- NBC News
Trump administration live updates: Vance to tout passage of GOP agenda bill; Senate to vote on spending clawbacks
What to know today GOP AGENDA BILL: Vice President JD Vance will deliver remarks in West Pittston, Pennsylvania, this afternoon to tout the passage earlier this month of the sweeping Republican domestic policy bill, which includes tax and Medicaid cuts and increases to border and defense spending. RESCISSIONS PACKAGE: The Senate is expected to vote on a $9.4 billion package of spending cuts requested by President Donald Trump, which would claw back previously approved funding for foreign aid and public broadcasting. ARIZONA ELECTION: Adelita Grijalva, the daughter of the late Rep. Raúl Grijalva, won the Democratic primary in Arizona's 7th Congressional District last night and will face Republican Daniel Butierez in a special election in September.
Telegraph
an hour ago
- Telegraph
Trump threatens tariffs on medicines within weeks
Donald Trump has threatened new tariffs on medicines within weeks as he steps up demands for drugmakers to move factories to the US. The president said he would impose tariffs on pharmaceutical imports 'probably at the end of the month', adding: 'We're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff.' It follows warnings earlier this month that tariffs could be as high as 200pc for medicines imported into the US. On Tuesday evening, the president suggested the new pharma tariffs could come alongside the 'reciprocal' rates which are expected to be implemented on Aug 1. Shares in European drugmakers including AstraZeneca, GSK, Novartis and Novo Nordisk dropped following Mr Trump's latest comments. Already, drug makers have been racing to bolster their presence in the US, with companies including GSK and Roche ramping up investment in US factories. Last month, reports suggested that AstraZeneca chief Sir Pascal Soriot had privately spoken of his desire to quit Britain for the US, shifting the company's listing away from London. It comes amid growing concern that the UK could be hit by new drug levies, despite agreeing a trade deal with Mr Trump. The UK is not as exposed as Ireland, which exports €58bn (£50bn) in pharma and chemicals to the US every year and has warned tariffs could slash this in half. However, the pharma sector still accounts for a large portion of the UK's exports to the US, with companies sending £8.8bn of pharmaceutical products to the US. Under the US-UK deal, ministers had pledged to make the UK more welcoming to US pharmaceutical companies, saying they would 'endeavour to improve the overall environment for pharmaceutical companies operating in the UK'. However, drugmakers warned that the UK was failing to deliver on that promise. They said the Government's long-awaited life sciences strategy – which was published on Wednesday – fell short on making Britain a better place to operate. The Government announced ambitions to reduce delays for clinical trials and said such plans would help make the UK the third-most important life sciences economy behind only the US and China by 2035. However, drug chiefs criticised the plans amid an ongoing row over NHS drugs charges. The Government has so far failed to reach an agreement with industry over how much the NHS is able to claw back in rebates on drugs. Johan Kahlström, managing director for healthcare company Novartis UK & Ireland, said he was 'deeply concerned and disappointed that, despite extensive engagement, the Government's new life sciences sector plan fails to address core industry concerns around the UK's investment environment'. Richard Torbett, from The Association of the British Pharmaceutical Industry, said: 'The UK must address the core issue holding back the life sciences sector, the long-term disinvestment in innovative medicines that is increasingly preventing NHS patients from accessing medications that are available in other countries. 'Without change, the UK will continue the slow slide down international league tables for research, investment, and the availability of new medicines.'
